Kisho Ohtani1, Takeo Fujino2, Tomomi Ide2, Kouta Funakoshi3, Ichirou Sakamoto2, Ken-Ichi Hiasa2, Taiki Higo2, Kenjiro Kamezaki4, Koichi Akashi4, Hiroyuki Tsutsui2. 1. Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. ohtani@cardiol.med.kyushu-u.ac.jp. 2. Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. 3. Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan. 4. Department of Medicine and Biosystemic Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract
BACKGROUND: Left ventricular (LV) dysfunction due to anthracycline-induced cardiotoxicity (AIC) has been believed to be irreversible. However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery. METHODS AND RESULTS: We thus retrospectively studied 350 cancer patients receiving anthracycline-based chemotherapy from 2001 to 2015 in our institution. Fifty-two patients (14.9%) developed AIC with a decrease in LV ejection fraction (LVEF) of 24.1% at a median time of 6 months [interquartile range (IQR) 4-22 months] after anthracycline therapy. By multivariate analysis, AIC was independently associated with cardiac comorbidities including ischemic heart disease, valvular heart disease, arrhythmia, and cardiomyopathy [odds ratio (OR) 6.00; 95% confidence interval (CI) 2.27-15.84, P = 0.00044), lower baseline LVEF (OR per 1% 1.09; 95% CI 1.04-1.14, P = 0.00034). During the median follow-up of 3.2 years, LV systolic dysfunction recovered among 33 patients (67.3%) with a median time of 4 months (IQR 2-6 months), which was independently associated with the introduction of standard medical treatment for HF (OR 9.39; 95% CI 2.27-52.9, P = 0.0014) by multivariate analysis. CONCLUSION: Early initiation of standard medical treatment for HF may lead to LV functional recovery in AIC.
BACKGROUND:Left ventricular (LV) dysfunction due to anthracycline-induced cardiotoxicity (AIC) has been believed to be irreversible. However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery. METHODS AND RESULTS: We thus retrospectively studied 350 cancerpatients receiving anthracycline-based chemotherapy from 2001 to 2015 in our institution. Fifty-two patients (14.9%) developed AIC with a decrease in LV ejection fraction (LVEF) of 24.1% at a median time of 6 months [interquartile range (IQR) 4-22 months] after anthracycline therapy. By multivariate analysis, AIC was independently associated with cardiac comorbidities including ischemicheart disease, valvular heart disease, arrhythmia, and cardiomyopathy [odds ratio (OR) 6.00; 95% confidence interval (CI) 2.27-15.84, P = 0.00044), lower baseline LVEF (OR per 1% 1.09; 95% CI 1.04-1.14, P = 0.00034). During the median follow-up of 3.2 years, LV systolic dysfunction recovered among 33 patients (67.3%) with a median time of 4 months (IQR 2-6 months), which was independently associated with the introduction of standard medical treatment for HF (OR 9.39; 95% CI 2.27-52.9, P = 0.0014) by multivariate analysis. CONCLUSION: Early initiation of standard medical treatment for HF may lead to LV functional recovery in AIC.
Entities:
Keywords:
Anthracycline; Cardiotoxicity; Heart failure; Medical treatment
Authors: D Cardinale; M T Sandri; A Martinoni; A Tricca; M Civelli; G Lamantia; S Cinieri; G Martinelli; C M Cipolla; C Fiorentini Journal: J Am Coll Cardiol Date: 2000-08 Impact factor: 24.094
Authors: Dawn L Hershman; Russell B McBride; Andrew Eisenberger; Wei Yann Tsai; Victor R Grann; Judith S Jacobson Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544
Authors: G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper Journal: N Engl J Med Date: 2000-04-13 Impact factor: 91.245
Authors: Lesley A Smith; Victoria R Cornelius; Christopher J Plummer; Gill Levitt; Mark Verrill; Peter Canney; Alison Jones Journal: BMC Cancer Date: 2010-06-29 Impact factor: 4.430
Authors: Yvonne Koop; Laura Dobbe; Angela H E M Maas; Dick Johan van Spronsen; Femke Atsma; Saloua El Messaoudi; Hester Vermeulen Journal: PLoS One Date: 2021-03-31 Impact factor: 3.240
Authors: Vera Vaz Ferreira; Tania Branco Mano; Isabel Cardoso; Madalena Coutinho Cruz; Luísa Moura Branco; Luís Almeida-Morais; Ana Timóteo; Ana Galrinho; Alexandra Castelo; Pedro Garcia Brás; Diana Simão; Mariana Sardinha; António Gonçalves; Rui Cruz Ferreira Journal: Int J Environ Res Public Health Date: 2022-02-28 Impact factor: 3.390